EUVIMEDEUVIMED entdecken
Crossref

CheckMate 9DW in advanced hepatocellular carcinoma: A new standard or a niche strategy?

Akhil Santhosh, Arndt Vogel

International Journal of Molecular and Immuno Oncology · 07.07.2026 · 11 · 108-112

DOI: 10.25259/ijmio_10_2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular and Immuno Oncology, online erschienen am 07.07.2026. Verfasst von Akhil Santhosh und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. For over a decade, the therapeutic landscape was dominated by tyrosine kinase inhibitors such as sorafenib and lenvatinib, with limited success. There has been a dramatic shift with the introduction of immune checkpoint inhibitors for the management of advanced disease. HCC develops in the background of a chronically inflamed and immunosuppressive hepatic microenvironment, making immunotherapy a biologically compelling option. Regimens such as IMbrave150 and HIMALAYA have shown significant improvements in overall survival (OS), but only a small fraction of patients get durable long-term benefit. Here, we dissect the latest dual immunotherapy regimen, nivolumab and ipilimumab, which showed an OS benefit versus lenvatinib and sorafenib in advanced unresectable HCC. The reported OS benefit is one of the highest so far in advanced HCC, but the study comes with its own caveats. Several challenges include the identification of predictive biomarkers, the management of immune-related toxicities, and the optimization of sequencing strategies. Through this brief commentary, we address key areas like selection of optimal patients with special focus on baseline liver function, comparison with other approved immunotherapy combinations, and toxicity management which is of utmost importance before this regimen can be primed for daily use. With a plethora of treatment options available, cost, infrastructure, and access become as important as translating trial endpoints into real-world practice.

Zitieren

APA

Santhosh, A., & Vogel, A. (2026). CheckMate 9DW in advanced hepatocellular carcinoma: A new standard or a niche strategy?. International Journal of Molecular and Immuno Oncology, 11, 108-112. https://doi.org/10.25259/ijmio_10_2026

Vancouver

Santhosh A, Vogel A. CheckMate 9DW in advanced hepatocellular carcinoma: A new standard or a niche strategy?. International Journal of Molecular and Immuno Oncology. 2026;11:108-112. doi:10.25259/ijmio_10_2026

BibTeX
@article{Santhosh2026,
  author = {Santhosh, Akhil and Vogel, Arndt},
  title = {CheckMate 9DW in advanced hepatocellular carcinoma: A new standard or a niche strategy?},
  journal = {International Journal of Molecular and Immuno Oncology},
  year = {2026},
  volume = {11},
  pages = {108--112},
  doi = {10.25259/ijmio_10_2026}
}
Kostenlos starten →